In this engaging conversation, Jake Chabon, Co-founder and CEO of Foresight Diagnostics, and Dr. Max Diehn, Scientific Advisor and Stanford professor, dive into the groundbreaking world of minimal residual disease (MRD) detection. They unveil Foresight's PhasED-Seq technology, which can identify cancer traces down to parts per ten million, and discuss its potential to transform cancer monitoring. The duo explores biopharma collaborations and the future of MRD testing in precision medicine. Expect fascinating insights on how MRD could redefine oncology surveillance!
